Locations:
Search IconSearch
July 29, 2021/Cancer

Virtual Care and Support for Adolescent and Young Adult Cancer Patients

How virtual visits for clinical trials and peer-to-peer support can improve access and care

21-CHP-2079243-Hero-650×450-1

Well before the start of the pandemic, Cleveland Clinic Children’s was leading virtual care and programming for adolescent and young adult (AYA) patients facing a cancer diagnosis. This existing infrastructure enabled a seamless shift and uninterrupted care for thousands of pediatric patients.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Stefanie Thomas, MD, MS, a pediatric oncologist and Director of the Adolescent and Young Adult Oncology Program at Cleveland Clinic Children’s, says there is a need for services in the virtual space to reach more patients, particularly those with rare cancers. Since Dr. Thomas joined the team in 2019, her clinical and research practice has focused on improving care and access for AYA patients at every point in their care journey.

In 2018, she led a study that assessed the rates of clinical trial enrollment in a group of pediatric and AYA cancer patients. Study findings, published in Cancer, suggest that significantly fewer AYA patients were enrolling in cancer clinical trials than children. These findings contradict conventional thinking that attributes trial existence and availability as barriers to participation.

Utilizing virtual visits for clinical trials

Leveraging virtual visits for clinical trials is a valuable tool to reach this patient population, argues Dr. Thomas. She recently presented best practices on this at a 2021 ASPHO Conference, sharing the following tips to maximize the virtual visit:

  • Set an agenda.
  • Have all clinical information beforehand including most recent scans.
  • Ensure there is a platform where you can share your screen to review imaging.
  • Discuss trial options.
  • Go over basic eligibility criteria and what could make the patient not eligible if they were to come in person.
  • Make documentation available as soon as possible for the patient to review.
  • Follow up in person only if AYA wants to enroll.

“We are one of only a few centers in the country offering clinical trials for new, innovative drugs. That means we have patients who come to us from all parts of the country, usually for a very specific trial. It’s essential that the patient and/or their guardian, really understands the goals and eligibility requirements of the trial before they spend time and money traveling to Cleveland,” she says.

Advertisement

A thorough assessment helps providers discuss the trial, understand the patient’s medical history and manage expectations with the patient and family. For patients who have been enrolled in longer-term oral medication-related studies, this format has allowed the team to do virtual check-ins, rather than having them come to the hospital.

Building community

The AYA program has also ventured into peer-to-peer community support through a virtual platform. Pre-pandemic planning for in-person programming transitioned to a virtual model in early 2020. Taylor Buss, MSW, LISW-S, pediatric and AYA Oncology Social Worker, oversees these programs.

She facilitates two virtual cancer chats for teens age 13 to 17 and young adults age 18 to 29, respectively. The latter is open to any young adult diagnosed with cancer and is not limited to patients being treated at Cleveland Clinic Children’s.

“Some patients are more comfortable accessing these chats from the comfort of their bedrooms. Coming into the hospital can be understandably burdensome, even triggering, for some patients.”

At the end of the day, it’s about building a community, says Ms. Buss. The offerings continue to evolve based on direct feedback from patients, she says. For example, they decided to reframe the virtual meet-ups as “cancer chats,” rather than “support groups.” Participants wanted something that felt less like therapy and more like a community, so, they are now hosting events like a virtual game night in partnership with community organizations.

Advertisement

The final word

In-person care and in-person community are both extremely important and are not going away. But, Dr. Thomas stresses, it’s important to also recognize the value of standardizing virtual options for select patients, even outside of clinical trials and peer-to-peer social support.

“Some patients don’t need to be physically present to receive their care, and we should recognize that and honor their desires, particularly in cases when they may be receiving bad news.”

Dr. Thomas does caution that moving forward, it will be important to consider how multidisciplinary care teams for AYA cancer patients can be incorporated into the virtual space.

“We need to make sure that the whole care team, including, for example, nurse coordinators, social workers and psychologists, remain integral to the management of care.”

Advertisement

Related Articles

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Ad